Last reviewed · How we verify

paclitaxel combined with platinum — Competitive Intelligence Brief

paclitaxel combined with platinum (paclitaxel combined with platinum) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane. Area: Oncology.

phase 3 Taxane Microtubules Oncology Small molecule Live · refreshed every 30 min

Target snapshot

paclitaxel combined with platinum (paclitaxel combined with platinum) — Fourth Affiliated Hospital of Guangxi Medical University. Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
paclitaxel combined with platinum TARGET paclitaxel combined with platinum Fourth Affiliated Hospital of Guangxi Medical University phase 3 Taxane Microtubules
Placebo plus Docetaxel Placebo plus Docetaxel Infinity Pharmaceuticals, Inc. marketed Taxane (microtubule stabilizer) Microtubules (β-tubulin)
Paclitaxel, Epirubicin Paclitaxel, Epirubicin Tianjin Medical University Cancer Institute and Hospital marketed Chemotherapy combination (taxane + anthracycline) Microtubules (paclitaxel); Topoisomerase II and DNA (epirubicin)
Paclitaxel, Carboplatin Paclitaxel, Carboplatin Queensland Centre for Gynaecological Cancer marketed Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (carboplatin)
nab-paclitaxel，Cisplatin nab-paclitaxel，Cisplatin Yang Jianjun, PhD marketed Chemotherapy combination (taxane + platinum agent) Microtubules (paclitaxel); DNA (cisplatin)
docetaxel and cisplatin docetaxel and cisplatin Sanofi marketed Chemotherapy combination (taxane + platinum agent) Microtubules (docetaxel); DNA (cisplatin)
Dose dense AC followed by T + trastuzumab Dose dense AC followed by T + trastuzumab Agendia marketed Chemotherapy regimen with monoclonal antibody HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane class)

  1. Sanofi · 3 drugs in this class
  2. Akeso · 1 drug in this class
  3. Fourth Affiliated Hospital of Guangxi Medical University · 1 drug in this class
  4. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
  5. Central European Society for Anticancer Drug Research · 1 drug in this class
  6. Chengdu Kanghong Biotech Co., Ltd. · 1 drug in this class
  7. Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
  8. Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
  9. Jina Pharmaceuticals Inc. · 1 drug in this class
  10. Air Force Military Medical University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). paclitaxel combined with platinum — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-combined-with-platinum. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: